Tag: ORIC

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) recently disclosed their fourth-quarter financial results, showing a loss of 49 cents per share, which ...

Wedbush analyst David Nierengarten has reaffirmed his bullish rating on ORIC Pharmaceuticals (NASDAQ: ORIC) and increased the price target to ...

On February 23, 2024, analyst Prakhar Agrawal from Cantor Fitzgerald began covering ORIC Pharmaceuticals (NASDAQ: ORIC) with an Overweight rating. ...